Skip to main content
Erschienen in: Journal of Experimental & Clinical Cancer Research 1/2016

Open Access 01.12.2016 | Erratum

Erratum to: Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway

verfasst von: Jianping Zhou, Xiaofei Zhi, Linjun Wang, Weizhi Wang, Zheng Li, Jie Tang, Jiwei Wang, Qun Zhang, Zekuan Xu

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2016

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Jianping Zhou, Xiaofei Zhi and Linjun Wang contributed equally to this work.
The online version of the original article can be found under doi:10.​1186/​s13046-015-0250-6.
The online version of the original article can be found at http://​dx.​doi.​org/​10.​1186/​s13046-015-0250-6.
Unfortunately, the original version of this article [1] contained several errors:
  • Table 1 included incorrect EGFR data. The EGFR data shown were obtained from patients with hepatocellular carcinoma rather than gastric cancer as indicated. These data were erroneously included during the drafting of the manuscript. The correct version of Table 1 showing the EGFR data obtained from gastric cancer patients can be found below. In addition, the correct version of Table 1 below does not show the TNM stage data reported in the original Table; as a result, the last sentence in the section “Cytoplasm located Linc00152 was increased in gastric cancer” should read “Here we found significant correlation with tumour size instead of tumour number, differentiation grade or metastasis.”
    Table 1
    Clinical relevance of Linc00152 and EGFR and patients with gastric cancer
     
    Linc00152
     
    EGFR
     
    Feather
    Low
    High
    P value
    Low
    High
    P value
    All cases
    36
    36
     
    36
    36
     
    Age
      
    0.326
      
    0.637
     <60
    11
    15
     
    13
    13
     
     ≥60
    25
    21
     
    23
    23
     
    Gender
      
    0.422
      
    0.061
     Male
    28
    25
     
    23
    30
     
     Female
    8
    11
     
    13
    6
     
    Differentiation grade
      
    0.616
      
    0.616
     Well
    18
    15
     
    15
    18
     
     Moderate
    16
    17
     
    17
    16
     
     Poorly
    2
    4
     
    4
    2
     
    Tumor Size(cm)
      
    0.004
      
    0.016
     ≤5 cm
    20
    8
     
    19
    9
     
     >5 cm
    16
    28
     
    17
    27
     
    Tumor Number
      
    0.772
      
    0.384
     Solitary
    28
    29
     
    30
    27
     
     Multiple
    8
    7
     
    6
    9
     
    Metastasis
      
    0.475
      
    0.812
     Yes
    22
    19
     
    20
    21
     
     No
    14
    17
     
    16
    15
     
  • In Figure 5, panel a was replicated as panel c. The correct Figure 5 can be found below.
  • The acknowledgements were given as “This work was supported by the Foundation for the Talents in Six Kinds of Profession of Jiangsu Province (JSGF2015D2914 to J.Z.); Natural Science Foundation of Jiangsu Province (BK20151136 to J.Z.).” Instead of “This work was supported by the Foundation for the Talents in Six Kinds of Profession of Jiangsu Province (WSW-075 to J.Z.); Natural Science Foundation of Jiangsu Province (BK20151136 to J.Z.); National Natural Science Foundation of China (81272712, 81072031 to Z.X.); the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 812111519 to Z.X.); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX 10231801 to Z.X.)”.
The correct Table 1 and Fig. 5c, as well as the acknowledgements, can be found below correctly.

Acknowledgements

This work was supported by the Foundation for the Talents in Six Kinds of Profession of Jiangsu Province (WSW-075 to J.Z.); Natural Science Foundation of Jiangsu Province (BK20151136 to J.Z.); National Natural Science Foundation of China (81272712, 81072031 to Z.X.); the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 812111519 to Z.X.); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX 10231801 to Z.X.).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J, et al. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res. 2015;34:135.PubMedCentralCrossRefPubMed Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J, et al. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res. 2015;34:135.PubMedCentralCrossRefPubMed
Metadaten
Titel
Erratum to: Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway
verfasst von
Jianping Zhou
Xiaofei Zhi
Linjun Wang
Weizhi Wang
Zheng Li
Jie Tang
Jiwei Wang
Qun Zhang
Zekuan Xu
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2016
Elektronische ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-015-0262-2

Weitere Artikel der Ausgabe 1/2016

Journal of Experimental & Clinical Cancer Research 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.